Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Q&A: Nat Shapo, Partner, Katten Muchin Rosenman

    Secondary Life Markets July 12, 2023By Greg Winterton
    Life Risk News Q&A
    Share
    Twitter LinkedIn Email

    The subject of enhanced cash surrender value offers (ECSVOs) made by life insurance companies in the United States during the past few years has caused a great deal of chagrin amongst those in the life settlement industry. Greg Winterton spoke to Nat Shapo, Partner at law firm Katten Muchin Rosenman, to get his views on the issue.

    GW: Nat, for those who might not be too familiar with ECSVOs, tell us what they are.

    NS: A few life insurers are making limited-time offers, by endorsements created many years after the creation of the policy form and the issuance of the policies, of substantially spiked cash surrender offers which are calculated by radically different methods than the benefit specification in the issued policy.  They are being made on specific blocks of universal life policies, usually with secondary guarantees, for the stated purpose of inducing policy terminations.

    GW: ECVSOs are a hot topic in life settlement circles, as they essentially put life insurance companies in competition with life settlement investors. Isn’t it a little disingenuous for life settlement investors to criticise competition? This is capitalism, after all.

    NS: Insurance is a heavily regulated form of capitalism.  Life insurers in order to be licensed must not violate the unfair discrimination prohibition and the Standard Nonforfeiture Law smoothness requirement, both of which, like all regulation, impede competition based on the legislature’s policy decision that treating like risks alike supersedes insurers’ ability to cut side deals which differ from the terms of the policies that everyone followed for years after they were issued.

    Life settlement companies are licensed for a very discrete, much different purpose than life insurers.  They do not group like risks together and spread and bear their risks.  Instead, they pay market value for seasoned policies. 

    A leading life insurance executive recognized this in testimony where he explained that state insurance code “laws prohibited insurers from giving more money for a policy to a customer over another. This was where life settlements come into the picture. Life settlement companies could discriminate on the market value of the policy.” 

    Life settlement companies follow a slew of consumer protection laws that life insurers evade in their ECSV offers, including rescission rights, intermediary fiduciary duty, verification of consumer competence, and disclosure of competing alternatives.  Each licensee should offer their own products and follow their own rules.

    GW: Last year, after the NCOIL (National Council of Insurance Legislators) summer meeting, it issued a press release, declaring that ‘certain’ ECVSO’s ‘violated the standard non-forfeiture law’. That implies that there are different types of ECVSOs. What are the differences here?

    NS: Life insurers have previously offered products with the same label, “enhanced cash surrender.”  This is a traditional product, offered by many insurers, with completely different characteristics.  There is no spike in cash surrender value many years into a seasoned policy never contemplated by the originally issued policy design.

     Instead, the traditional enhanced cash surrender product featured higher cash values in earlier years to help with the accounting treatment of employee benefits.  This is nothing like the ECSV products which are at issue today, which have only been offered for a few years by a few insurers.

    GW: The state of Montana recently issued an Advisory Memorandum to life insurance companies, stating that ECVSOs were not compliant with some provisions of the Montana Insurance Code. Other states have done something similar. Does this mean that the risk that ECVSOs present to the life settlement market is receding?

    NS: Nine states have taken some kind of action with respect to ECSVs.  This includes two states who recently rescinded all four previous approvals for these products.  This is good progress which we hope will spur action in more states.

    GW: If you’re an end investor in a life settlement fund, what do you need to be asking your manager about the ECVSO issue? Are there any other risks that ECVSOs present to the market that they should be aware of?

    NS: Once an investor owns a policy, ECSV offers do not pose a direct risk to that investment, since the investor has a contract with the insurer and can pay premiums until the death benefit can be claimed.  The issue is a macro one for all stakeholders in the life settlement market—ECSVs may take policies which would be candidates for future life settlements out of commerce before the consumer is made aware that his or her asset might have a secondary market value.

     

    Nat Shapo is a Partner at Katten Muchin Rosenman

    2023 - July Life Settlements Longevity Risk Q&A Volume 2 Issue 7 - July 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026By Greg Winterton

    Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

    November 11, 2026By LMI Newsdesk

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026By Greg Winterton

    Q&A: Alexandr Dudarev, CEO, Inshurik

    October 28, 2026By Greg Winterton
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.